New therapeutic options for gout;Nouveaux traitements de la goutte

Presse Medicale

Volumn 40, Issue 9, 2011, Pages 844-849

  Richette, Pascal ^a   Ottaviani, Sébastien ^a   Bardin, Thomas ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT; CANAKINUMAB; FEBUXOSTAT; PEGLOTICASE; RDEA 594; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; UNCLASSIFIED DRUG;

DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GOUT; HUMAN; HYPERURICEMIA; PATHOGENESIS; SHORT SURVEY;

ALLOPURINOL; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; GOUT; GOUT SUPPRESSANTS; HUMANS; INTERLEUKIN-1BETA; ORGANIC ANION TRANSPORTERS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THIAZOLES; URATE OXIDASE;

EID: 80052295296     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.02.043     Document Type: Short Survey

References (29)

1. Wu X.W., Muzny D.M., Lee C.C., Caskey C.T. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992, 34:78-84.
2. Richette P., Bardin T. Gout. Lancet 2010, 375:318-328.
3. Richette P., Briere C., Hoenen-Clavert V., Loeuille D., Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007, 34:2093-2098.
4. Terkeltaub R. Learning how and when to employ uricase as bridge therapy in refractory gout. J Rheumatol 2007, 34:1955-1958.
5. Burns C.M., Wortmann R.L. Gout therapeutics: new drugs for an old disease. Lancet 2011, 377:165-177.
6. Sherman M.R., Saifer M.G., Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008, 60:59-68.
7. Sundy J.S., Ganson N.J., Kelly S.J., Scarlett E.L., Rehrig C.D., Huang W., et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021-1028.
8. Sundy J.S., Becker M.A., Baraf H.S., Barkhuizen A., Moreland L.W., Huang W., et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 2008, 58:2882-2891.
9. Anderson A., Singh J.A. Pegloticase for chronic gout. Cochrane Database Syst Rev 2010, 3:CD008335.
10. Baraf H.S., Matsumoto A.K., Maroli A.N., Waltrip R.W. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 2008, 58:3632-3634.
11. Schlesinger N., Yasothan U., Kirkpatrick P. Pegloticase. Nat Rev Drug Discov 2011, 10:17-18.
12. Schumacher H.R., Becker M.A., Wortmann R.L., Macdonald P.A., Hunt B., Streit J., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59:1540-1548.
13. Becker M.A., Schumacher H.R., Wortmann R.L., MacDonald P.A., Eustace D., Palo W.A., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
14. Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
15. Becker M.A., Schumacher H.R., Wortmann R.L., MacDonald P.A., Palo W.A., Eustace D., et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a 28-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005, 52:916-923.
16. Reinders M.K., Haagsma C., Jansen T.L., van Roon E.N., Delsing J., van de Laar M.A., et al. A randomized controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600mg/day versus benzbromarone 100-200mg/day in patients with gout. Ann Rheum Dis 2009, 68:892-897.
17. Hande K.R., Noone R.M., Stone W.J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47-56.
18. Jansen T.L., Richette P., Perez-Ruiz F., Tausche A.K., Guerne P.A., Punzi L., et al. International position paper on febuxostat. Clin Rheumatol 2010, 29:835-840.
19. Becker M.A., Schumacher H.R., Espinoza L.R., Wells A.F., MacDonald P., Lloyd E., et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010, 12:R63.
20. Schlesinger N. New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. Curr Rheumatol Rep 2010, 12:130-134.
21. Pope R.M., Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 2007, 56:3183-3188.
22. Busso N., So A. Mechanisms of inflammation in gout. Arthritis Res Ther 2010, 12:206.
23. Chauffier K., London J., Beaudouin C., Fautrel B. Indications of anakinra. Presse Med 2009, 38:799-807.
24. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
25. McGonagle D., Tan A.L., Shankaranarayana S., Madden J., Emery P., McDermott M.F. Management of treatment-resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007, 66:1683-1684.
26. Gratton S.B., Scalapino K.J., Fye K.H. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 2009, 61:1268-1270.
27. Chen K., Fields T., Mancuso C.A., Bass A.R., Vasanth L. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010, 40:210-214.
28. Terkeltaub R., Sundy J.S., Schumacher H.R., Murphy F., Bookbinder S., Biedermann S., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomized, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
29. So A., De Meulemeester M., Pikhlak A., Yucel A.E., Richard D., Murphy V., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.